The further evolution of biotech

Keywords

Biotechnology, Pharmaceutical industry, Business, Drug development, Drug industry

References

• A 4-Mb high-density single nucleotide polymorphism-based map around human APOE.Yi‐Ling Hsieh — 1998
• Pharmacogenomic-guided drug development: regulatory perspectiveTimothy J. Poulin — 2002
• The evolution of biotechCarilee Berg, Rena Nassr, Kevin Pang — 2002
• The future for stem cell researchRobin Lovell‐Badge — 2001
• Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium.Lindsay A. Farrer — 1997
• Single-nucleotide polymorphism alleles in the insulin receptor gene are associated with typical migraine.Linda McCarthy, David A. Hosford, John Riley — 2001
• Association between apolipoprotein E genotype and Alzheimer disease in African American subjects.Neill R. Graff‐Radford, Robert C. Green, Rodney C.P. Go — 2002
• Clinical proteomics: translating benchside promise into bedside realityEmanuel F. Petricoin, Kathryn C. Zoon, Elise C. Kohn — 2002
• Genome-based pharmacogenetics and the pharmaceutical industryAllen D. Roses — 2002
• Stem cells in tissue engineeringPaolo Bianco, Pamela Gehron Robey — 2001
• Identification of a psoriasis susceptibility candidate gene by linkage disequilibrium mapping with a localized single nucleotide polymorphism map.D. Hewett, Lena Samuelsson, Joanne Polding — 2002
• The impact of pharmacogenetics and pharmacogenomics on drug discoveryKlaus Lindpaintner — 2002
• Apolipoprotein E alleles as risk factors in Alzheimer's disease.Allen D. Roses — 1996
• Genotypes and phenotypes for apolipoprotein E and Alzheimer disease in the Honolulu-Asia aging study.J. W. P. F. Kardaun, Lon R. White, Helaine E. Resnick — 2000
• Proteomics in drug discovery.Jack H. Wang, Rodney M Hewick — 1999
• Pentair Inc, USA2002
• The APOE-∊4 Allele and the Risk of Alzheimer Disease Among African Americans, Whites, and HispanicsMing‐Xin Tang — 1998
• The APOE-(cid:101) 4 Allele and the Risk of Alzheimer Disease Among African Americans, Whites, and HispanicsPhD Ming-Xin Tang, PhD Yaakov Stern, MD Mph Karen Marder

Cited by

• Adverse events/mode of action relationship of monoclonal antibodies-based therapies : overview of marketed produts in the European UnionF. Lemos — 2014
• Design and synthesis of multifunctional poly(ethylene glycol)s using enzymatic catalysis for multivalent cancer drug deliveryKwang Su Seo — 2012
• Developing Novel Electrospray Ionization Mass Spectrometry (esi ms) Techniques to Study Higher Order Structure and Interaction of BiopolymersAgya K. Frimpong — 2009
• Challenges in commercializing stem cells and regenerative medicine technologies: A case study on dedicated biotech firms in JapanHawa Issa Munisi, Shintaro Sengoku — 2013
• The intersection of biotechnology and pharmacogenomics: health policy implications.Kathryn A. Phillips — 2006
• Risk-based strategy for the assessment of pharmacokinetic drug-drug interactions for therapeutic monoclonal antibodies.Honghui Zhou, Hugh M. Davis — 2009
• Balancing US patent and FDA approval processes: strategically optimizing market exclusivity.Dennis S. Fernandez, JAMES T. HUIE — 2004
• The dawning era of polymer therapeuticsRuth Duncan — 2003
• The biotechnology industry: What's next?Pierre A. Guertin — 2009
• Pharmacokinetic aspects of biotechnology products.Lisa Tang, Adam M. Persky, Günther Hochhaus — 2004
• Xentry, a new class of cell-penetrating peptide uniquely equipped for delivery of drugsKristopher Montrose, Yi Yang, Xueying Sun — 2013
• HTS technologies in biopharmaceutical discovery.Ge Wu, Stephen K. Doberstein — 2006
• Biomarkers in drug discovery and development.Ray Bakhtiar — 2008
• Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application.Mark J. Millan — 2006
• A journey of hope: lessons learned from studies on rare diseases and orphan drugsMaja Wästfelt, Bengt Fadeel, Jan‐Inge Henter — 2006
• Market Metrics: The Future of the Biotech Industry in the UK — What Structural Changes Lie Ahead?Alistair M. Howseman — 2006
• A bibliometric analysis of global research on genome sequencing from 1991 to 2010Yidan Sun, Hui‐Zhen Fu, Yuh‐Shan Ho — 2013
• Nanomedicine for the prevention, treatment and imaging of atherosclerosis.Costas Psarros, Regent Lee, Marios Margaritis — 2012
• A nanoformulation containing a scFv reactive to electronegative LDL inhibits atherosclerosis in LDL receptor knockout mice.Marcela Frota Cavalcante, Soraya Megumi Kazuma, Eduardo André Bender — 2016
• Bioreactors for tendon tissue engineering: challenging mechanical demands towards tendon regenerationGonçalves, A I, Berdecka, Dominika, Rodrigues, Márcia T. — 2018

Related papers

• Translational pharmacokinetic-pharmacodynamic analysis in the pharmaceutical industry: an IQ Consortium PK-PD Discussion Group perspective.Harvey Wong, Tonika Bohnert, Valeriu Damian‐Iordache — 2017
• Facts, Fiction, and the Pharmaceutical IndustryJohn Lloyd Hanson — 1986
• Voluntary control of drug promotion in Sweden.E Perman — 1990
• The pharmaceutical industry as a political player.John Abraham — 2002
• Excess in the pharmaceutical industryMarcia Angell — 2004
• [Physicians and drug industry: attitudes and practice].Olaf Gjerløw Aasland, Rei­dun Før­de — 2004
• Mecanismos de regulación en la industria farmacéutica española: una valoración del Pacto de Estabilidad Gobierno-Industria Farmacéutica 2001-2004 .Enzo Piña Mavarez, María Eugenia Suárez-Serrano — 2009
• Gifts to physicians from industry.Keith Bauer — 2000
• Does family medicine have a professional obligation to play a leading role in pharmaceutical industry-sponsored drug research?: yes.Anthony D’Urzo — 2011